source
- Enlivex cuts 60% of staff, halts preclinical R&D and slashes exec salaries to fund osteoarthritis trialEnlivex, an Israeli biotech developing a cell‑based immunotherapy called allocetra for knee osteoarthritis, announced today that it is reducing its workforce by 60 percent. The cut reduces the sta…
- Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer winGermany’s Merck KGaA has picked up Silence Therapeutics to the tune of $1.3 billion in the wake of the British biotech’s mid-stage success for its challenger to Takeda’s Mimrylo.